Depomed Licenses Acuform® Patents to Janssen Pharmaceuticals, Inc. MENLO PARK, Calif., Aug. 27, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq: DEPO) today announced that Janssen Pharmaceuticals, Inc., ...
BURLINGTON, Mass. and MENLO PARK, Calif., June 20, 2011 (GLOBE NEWSWIRE) -- inVentiv Health, offering best-in-class clinical, consulting and commercial services to the healthcare industry, and Depomed ...
Up to $64M in milestone payments could be realized. Covidien has licensed worldwide rights to utilize Depomed’s AcuForm™ gastric retentive drug delivery technology for the exclusive development of ...
MENLO PARK, Calif., Oct 12, 2009 -- Depomed, Inc. (NASDAQ:DEPO) announced today top-line results from the BREEZE 1 and 2 Phase 3 clinical trials evaluating the safety and efficacy of SeradaTM, an ...
Biovail shells out upfront fee of $500,000. Biovail gained access to Depomed’s AcuForm™ drug delivery technology for the development of up to two products. Biovail may select these products from an ...
Depomed Comments on FDA Guidance and Plans for One Additional Phase 3 Clinical Trial Evaluating Non-Hormonal Therapy for Menopausal Hot Flashes MENLO PARK, Calif., Jan 19, 2010 (BUSINESS WIRE) -- ...
MENLO PARK, Calif., Sept. 17, 2010 (GLOBE NEWSWIRE) -- Depomed, Inc. (Nasdaq:DEPO) announced today that its president and chief executive officer, Carl A. Pelzel will be presenting at the UBS Global ...
MENLO PARK, Calif.--(BUSINESS WIRE)--Depomed, Inc. (NASDAQ:DEPO) today announced that in its Phase 1 pharmacokinetic study in Parkinson’s patients, DM-1992, Depomed’s investigative novel gastric ...
MENLO PARK, Calif., Aug. 27, 2012 /PRNewswire/ -- Depomed, Inc. (Nasdaq:DEPO) today announced that Janssen Pharmaceuticals, Inc., has licensed rights to Depomed's Acuform gastric retentive drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results